drugset / Trial / NCT01103024
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |